This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:othertreatments:chemotherapy [05.02.2011] – external edit 127.0.0.1 | home:othertreatments:chemotherapy [11.13.2011] – [Rituximab] paulalbert | ||
---|---|---|---|
Line 39: | Line 39: | ||
It is not harmful to the body to discontinue MTX abruptly. This is in contrast to Prednisone, where abruptly stopping can cause a number of serious problems. Some doctors think there is a risk of rebound inflammation from stopping methotrexate abruptly. Taking a few weeks to wean from MTX, while probably not necessary, is the cautious approach to avoid the symptoms of rebound inflammation. | It is not harmful to the body to discontinue MTX abruptly. This is in contrast to Prednisone, where abruptly stopping can cause a number of serious problems. Some doctors think there is a risk of rebound inflammation from stopping methotrexate abruptly. Taking a few weeks to wean from MTX, while probably not necessary, is the cautious approach to avoid the symptoms of rebound inflammation. | ||
+ | |||
+ | ===== Rituximab ===== | ||
+ | |||
+ | |||
+ | In 2011, a Norwegian study published in //PLoS One// studied the effect of Rituximab – a monoclonal antibody otherwise used in cancers and anti-rejection treatment for organ transplants – on patients with chronic fatigue syndrome. In the 25-week study period, fatigue improved significantly in 10 out of 15 patients versus 2 out of 15 controls.(({{pubmed> | ||
+ | |||
===== Patient interviews | ===== Patient interviews | ||